4 results on '"Menke-van der Houven van Oordt, C. Willemien"'
Search Results
2. 89 Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs.
- Author
-
Miedema, Iris H. C., Wijngaarden, Jessica E., Pouw, Johanna E. E., Zwezerijnen, Gerben J. C., Sebus, Hylke J., Smit, Egbert, de Langen, Adrianus J., Bahce, Idris, Thiele, Andrea, Vugts, Daniëlle J., Boellaard, Ronald, Huisman, Marc C., and Menke-van der Houven van Oordt, C. Willemien
- Subjects
BRAIN ,IMMUNE checkpoint inhibitors ,KIDNEYS ,RADIOISOTOPES ,ORGANS (Anatomy) ,MONOCLONAL antibodies ,IMMUNE system ,BLOOD collection ,POSITRON emission tomography ,RESEARCH funding ,SPLEEN ,BONE marrow - Abstract
Simple Summary: The uptake on a
89 Zr-immuno-PET scan is not just the result of the binding of a radiolabeled antibody with its target (i.e., target engagement) but also includes background factors such as non-specific binding (for example, catabolism of antibodies inside endothelial cells). In this study, we wanted to isolate target engagement. We used data from five previously performed89 Zr-immuno-PET studies with immune-targeting89 Zr-radiolabeled antibodies. First, via Patlak analysis, we separated reversible from irreversible uptake, and by using a baseline of target-negative organs, we further defined target-specific irreversible uptake. Second, we compared different mass doses (ratios of labeled and unlabeled antibody) and looked for saturation effects. Evidence for target engagement was based on the following two things: (1) when the target-specific irreversible uptake exceeded the baseline, and (2) when the signal showed saturation. We found target engagement for the different antibodies in several lymphoid organs, for example, in the spleen, while the brain had close to zero target engagement. We propose a new baseline for bone marrow and brain. In conclusion, we promote the use of Patlak analysis for89 Zr-immuno-PET studies, or similar simplified outcomes such as a tissue-to-blood ratio. Introduction:89 Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies ([89 Zr]Zr-mAbs)) can be used to study the biodistribution of mAbs targeting the immune system. The measured uptake consists of target-specific and non-specific components, and it can be influenced by plasma availability of the tracer. To find evidence for target-specific uptake, i.e., target engagement, we studied five immune-checkpoint-targeting [89 Zr]Zr-mAbs to (1) compare the uptake with previously reported baseline values for non-specific organ uptake (ns-baseline) and (2) look for saturation effects of increasing mass doses. Method:89 Zr-immuno-PET data from five [89 Zr]Zr-mAbs, i.e., nivolumab and pembrolizumab (anti-PD-1), durvalumab (anti-PD-L1), BI 754,111 (anti-LAG-3), and ipilimumab (anti-CTLA-4), were analysed. For each mAb, 2–3 different mass doses were evaluated. PET scans and blood samples from at least two time points 24 h post injection were available. In 35 patients, brain, kidneys, liver, spleen, lungs, and bone marrow were delineated. Patlak analysis was used to account for differences in plasma activity concentration and to quantify irreversible uptake (Ki ). To identify target engagement, Ki values were compared to ns-baseline Ki values previously reported, and the effect of increasing mass doses on Ki was investigated. Results: All mAbs, except ipilimumab, showed Ki values in spleen above the ns-baseline for the lowest administered mass dose, in addition to decreasing Ki values with higher mass doses, both indicative of target engagement. For bone marrow, no ns-baseline was established previously, but a similar pattern was observed. For kidneys, most mAbs showed Ki values within the ns-baseline for both low and high mass doses. However, with high mass doses, some saturation effects were seen, suggestive of a lower ns-baseline value. Ki values were near zero in brain tissue for all mass doses of all mAbs. Conclusion: Using Patlak analysis and the established ns-baseline values, evidence for target engagement in (lymphoid) organs for several immune checkpoint inhibitors could be demonstrated. A decrease in the Ki values with increasing mass doses supports the applicability of Patlak analysis for the assessment of target engagement for PET ligands with irreversible uptake behavior. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
- Author
-
Werter, Inge M., primary, Remmelzwaal, Sharon, additional, Burchell, George L., additional, de Gruijl, Tanja D., additional, Konings, Inge R., additional, van der Vliet, Hans J., additional, and Menke-van der Houven van Oordt, C. Willemien, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol.
- Author
-
Geboers, Bart, Timmer, Florentine E. F., Ruarus, Alette H., Pouw, Johanna E. E., Schouten, Evelien A. C., Bakker, Joyce, Puijk, Robbert S., Nieuwenhuizen, Sanne, Dijkstra, Madelon, van den Tol, M. Petrousjka, de Vries, Jan J. J., Oprea-Lager, Daniela E., Menke-van der Houven van Oordt, C. Willemien, van der Vliet, Hans J., Wilmink, Johanna W., Scheffer, Hester J., de Gruijl, Tanja D., and Meijerink, Martijn R.
- Subjects
PANCREATIC tumors ,ADENOCARCINOMA ,METASTASIS ,IMMUNOSUPPRESSION ,RANDOMIZED controlled trials ,ELECTROPORATION ,NIVOLUMAB ,ELECTROTHERAPEUTICS ,COMBINED modality therapy ,CANCER vaccines ,COMPUTED tomography ,TOLL-like receptors ,LIGANDS (Biochemistry) ,IMMUNOTHERAPY ,PATIENT safety ,EMISSION-computed tomography - Abstract
Simple Summary: Metastatic pancreatic ductal adenocarcinoma has a dismal prognosis, and to date no curative treatment options exist. The image guided tumor ablation technique irreversible electroporation (IRE) employs high-voltage electrical pulses through the application of several needle electrodes in and around the tumor in order to induce cell death. IRE ablation of the primary tumor has the ability to reduce pancreatic tumor induced immune suppression while allowing the expansion of tumor specific effector T cells, hereby possibly shifting the pancreatic tumor microenvironment into a more immune permissive state. The addition of immune enhancing therapies to IRE might work synergistically and could potentially induce a clinically significant treatment effect. This study protocol describes the rationale and design of the PANFIRE-III trial that aims to assess the safety of the combination of IRE with IMO-2125 (toll-like receptor 9 ligand) and/or nivolumab in patients with metastatic pancreatic ductal adenocarcinoma. Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique with the ability to generate a window for the establishment of systemic antitumor immunity. IRE transiently alters the tumor's immunosuppressive microenvironment while simultaneously generating antigen release, thereby instigating an adaptive immune response. Combining IRE with immunotherapeutic drugs, i.e., electroimmunotherapy, has synergistic potential and might induce a durable antitumor response. The primary objective of this study is to assess the safety of the combination of IRE with IMO-2125 (a toll-like receptor 9 ligand) and/or nivolumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). In this randomized controlled phase I clinical trial, 18 patients with mPDAC pretreated with chemotherapy will be enrolled in one of three study arms: A (control): nivolumab monotherapy; B: percutaneous IRE of the primary tumor followed by nivolumab; or C: intratumoral injection of IMO-2125 followed by percutaneous IRE of the primary tumor and nivolumab. Assessments include contrast enhanced computed tomography (ceCT),
18 F-FDG and1 8 F-BMS-986192 (PD-L1) positron emission tomography (PET)-CT, biopsies of the primary tumor and metastases, peripheral blood samples, and quality of life and pain questionnaires. There is no curative treatment option for patients with mPDAC, and palliative chemotherapy regimens only moderately improve survival. Consequently, there is an urgent need for innovative and radically different treatment approaches. Should electroimmunotherapy establish an effective and durable anti-tumor response, it may ultimately improve PDAC's dismal prognosis. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.